Suzhou, China
August 21, 2026

BioDlink International Company Limited ("BioDlink "; Stock Code:1875.HK) announces its unaudited interim results for the six‑month period ended June 30, 2026.

• CDMO revenue reached RMB199 million, representing a period‑over‑period increase of 157.0%.
• Cumulative customer base totaled 116，including 16 customers from overseas, reflecting continued global market expansion.
• Total CMC projects stood at 134, with 14 new CMC projects secured in H1 2026.
• PPQ* pipeline continued to expand: 6 cumulative PPQ projects secured.
• First commercial‑CDMO assignment secured: formal commercial manufacturing order for Lepu Biopharma’s ADC, Meiyouheng^®.
• Order backlog totaled RMB 391 million, up 95.5% period‑over‑period.
• Recognized as an outstanding innovation case in the 2025 White Paper on Innovative Drugs and Supply Chains, and awarded "Emerging CDMO of the Year" by IMAPAC

Note: * PPQ: Process Performance Qualification

Dr. Jimmy Li, Chairman of BioDlink said:“ The first half of 2026 marked an important milestone as BioDlink completed its first reporting period as part of the WuXi XDC platform. Our solid results demonstrate the strength of our integrated bioconjugate CDMO offering and continued market demand. We achieved smooth integration progress during the period and further strengthened our end-to-end ADC manufacturing capabilities. Going forward, we will leverage the combined strengths of BioDlink and WuXi XDC to support customers’ development and commercialization needs, capture growth opportunities in the expanding XDC market, and deliver sustainable value to all stakeholders.”

Dr. Jian Zhang, Acting CEO of BioDlink said:“ In the first half of 2026, during the post-merger integration transition, BioDlink's overall workforce remained stable, maintaining high-quality execution and strong operational efficiency. The CDMO business delivered robust growth, with solid progress across order intake, project development and customer expansion. Leveraging its established process development expertise and efficient execution capabilities, together with a well-developed global customer network and mature commercial capabilities, BioDlink continued to capture growth opportunities in the global conjugated therapeutics market and sustain healthy business growth.”

Part 1
H1 2026 Performance Highlights

Robust CDMO Growth: In H1 2026, the Group's CDMO business delivered strong momentum, with an expanded project funnel and order backlog. 14 new CMC projects were added during the period, including 2 projects each with a contract value exceeding US$1.5 million, bringing total CMC projects to 134. Order backlog (signed but unfulfilled) reached RMB 391 million, up 95.5% period over period.

Global Expansion of self‑developed products: The Group continued to shift its self‑developed products footprint toward international markets. Pusintin® (Bevacizumab Injection) obtained marketing approvals in two additional overseas jurisdictions, bringing the total number of approved markets to seven.

Key Financial Overview: For the reporting period, the Group recorded total revenue of RMB 246 million. CDMO revenue reached RMB 199 million, surging 157% period over period. Driven by the strategic business transformation, self‑developed products sales revenue stood at RMB 45 million, down 88.6% period over period. Gross profit totaled RMB 53 million, representing a period over period decrease of 85.1%, with gross profit margin at 21.4%.

Acquisition & Integration Update: WuXi XDC (2268.HK) completed its voluntary conditional cash offer for the Company on 31 March 2026 and, as of 30 June 2026, holds approximately 60.67% of the Company's shares as its controlling shareholder. The Group actively pursued integration into the WuXi XDC ecosystem throughout the period. The Group entered into continuing connected transaction agreements (CCT Agreements) with WuXi XDC and a connected transaction agreement (CT Agreement) with WuXi Biologics (Cayman) Inc. (2269.HK). These arrangements enable the Group to better leverage its existing infrastructure and technical capabilities to capture future commercial opportunities.

Part 2
Customer & Project Highlights for H1 2026

BioDlink's CDMO business delivered solid growth in H1 2026

• 8 new customers and 14 new CMC projects added; Total serviced 236 projects, including 102 discovery and 134 CMC projects.

• 2 new PPQ assignments in H1 2026, with 3 batches scheduled and 2 successfully delivered. One commercial‑scale assignment secured, unlocking future revenue streams.
• Improved order‑book mix: total customers served stand at 116. As we continue expanding our global footprint, overseas, Hong Kong, Macau and Taiwan customers total 22, representing 19% of the customer base.
• Order backlog (signed but unfulfilled) reached RMB 391 million, up 95.5% period‑over‑period.

Broad‑based CDMO progress across diverse project stages

Projects increased across all development stages, with continued expansion of the early-stage funnel. Discovery and pre-clinical projects increased to 176.

Notes: All projects in the business funnel are assessed following BioDlink's project criteria；
(1) Cumulative number of projects as of June 30, 2026
(2) The small-sized figures represent project numbers as of Dec 31, 2025, and the CMC project count has been revised following the consolidation of 3 duplicate projects.

Expanding molecular modalities with steady wins from key customers
The Group has advanced a broad portfolio of biotherapeutic development projects, covering mAbs, bispecifics, multispecifics, bispecific ADCs and dual‑payload ADCs, demonstrating increasing project diversity. Backed by robust end‑to‑end development and manufacturing capabilities, deeper collaborations with key customers underpin long‑term business growth.

Part 3

Advancing Diversified Technology Platforms

BioDlink continues to enhance its suite of proprietary technology platforms, building an integrated, self‑sufficient R&D and manufacturing system and reinforcing its core technological moat in ADC CDMO services.

GL‑DisacLink^® — a co‑developed ADC site‑specific glycosylation conjugation platform
Fully embedded within the Group's CDMO service offering, the platform enables customers to develop potential best‑in‑class ADC candidates. Among them, the first programme supported by the platform to secure FDA IND approval completed end-to-end ADC process development, GMP manufacturing and FDA IND submission within four months. As of 30 June 2026, close to 500 early‑stage innovative molecular programmes have been supported by this platform.

Proprietary BDKcell^® (CHO‑K1) Cell‑Line Platform and BDKMedia™ Custom Media Platform
BDKcell^® (CHO‑K1) supports cell‑line development for mAbs, bispecific antibodies, fusion proteins and ADC payload‑carrier antibodies. Paired with in‑house BDKMedia™ custom media, it enables self‑sufficient upstream R&D and manufacturing supply chains while optimising production costs. From its launch in 2025 to 30 June 2026, 13 early‑stage research assignments and 9 DNA‑initiated CMC assignments have been secured.

Proprietary BDKLyo^® Intelligent Lyophilisation Modelling Platform
Built on QbD principles, the platform significantly accelerates lyophilisation process development for IND‑enabling studies, reducing conventional timelines by more than 50% and requiring just 1‑2 experimental rounds. Featuring high prediction accuracy and strong robustness, it shortens overall CMC timelines and reduces consumable and energy costs. It is widely used for lyophilised formulations of high‑end biologics and ADCs.

Part 4
Commercialised Products & R&D Progress

Proprietary drug development remains a core strategic pillar for the Group. During the reporting period, the Group continued optimisation and validation work for cell‑line development, while advancing the global commercialisation of its marketed in‑house assets to maximise the long‑term value of its innovation portfolio.

Commercial Products
Pusintin^® (Bevacizumab Injection) has received regulatory acceptance for marketing applications from authorities in 29 overseas jurisdictions, with approvals granted in seven markets. New marketing clearances were obtained in Syria and Mexico during H1 2026.

R&D Progress
The Group continued to advance its proprietary R&D initiatives by optimising multiple genetically engineered CHO cell lines. Leveraging this platform, the Group progressed several biosimilar candidates in early-stage development, focusing on cell line development and process optimisation to support future sample development and platform validation.

Collaborative Progranme — TAB014 (Bevacizumab Intravitreal Injection Solution): Commercial partner Zhaoke Ophthalmology (6622.HK) submitted its NDA for this Class 3.2 drug in June 2025. Approval is anticipated in late‑2026 to early‑2027. The Group will undertake subsequent commercial manufacturing and is entitled to sales‑related royaltie.

Note: All project data are assessed following BioDlink's project criteria.

Key Financials Performance